Vincent Medical Holdings Limited
Vincent Medical Holdings Limited (1612.HK) Stock Competitors & Peer Comparison
See (1612.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 1612.HK | HK$0.86 | -1.15% | 559.7M | 7.91 | HK$0.11 | +3.79% |
| 0853.HK | HK$13.76 | -0.79% | 24.2B | -13.73 | -HK$0.95 | N/A |
| 2252.HK | HK$21.98 | +0.09% | 21.7B | -29.44 | -HK$0.72 | N/A |
| 1302.HK | HK$2.16 | -0.92% | 9.1B | 34.50 | HK$0.06 | N/A |
| 2172.HK | HK$14.41 | -7.45% | 8.8B | 31.31 | HK$0.48 | +1.26% |
| 1858.HK | HK$15.40 | -2.59% | 8.4B | 43.00 | HK$0.36 | +0.94% |
| 1789.HK | HK$6.89 | +1.92% | 7.5B | 25.85 | HK$0.26 | +1.07% |
| 2190.HK | HK$22.70 | +0.89% | 7B | 67.94 | HK$0.33 | +0.49% |
| 6606.HK | HK$14.14 | +0.00% | 6.3B | 58.92 | HK$0.24 | N/A |
| 1763.HK | HK$18.96 | +4.12% | 6B | 12.88 | HK$1.39 | +2.33% |
Stock Comparison
1612.HK vs 0853.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 0853.HK has a market cap of 24.2B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 0853.HK trades at HK$13.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 0853.HK's P/E ratio is -13.73. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 0853.HK's ROE of -0.33%. Regarding short-term risk, 1612.HK is less volatile compared to 0853.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 0853.HK's competition here
1612.HK vs 2252.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2252.HK has a market cap of 21.7B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2252.HK trades at HK$21.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2252.HK's P/E ratio is -29.44. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2252.HK's ROE of -2.32%. Regarding short-term risk, 1612.HK is less volatile compared to 2252.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 2252.HK's competition here
1612.HK vs 1302.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 1302.HK has a market cap of 9.1B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 1302.HK trades at HK$2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 1302.HK's P/E ratio is 34.50. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 1302.HK's ROE of +0.06%. Regarding short-term risk, 1612.HK is less volatile compared to 1302.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 1302.HK's competition here
1612.HK vs 2172.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2172.HK has a market cap of 8.8B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2172.HK trades at HK$14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2172.HK's P/E ratio is 31.31. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2172.HK's ROE of +0.15%. Regarding short-term risk, 1612.HK is less volatile compared to 2172.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 2172.HK's competition here
1612.HK vs 1858.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 1858.HK has a market cap of 8.4B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 1858.HK trades at HK$15.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 1858.HK's P/E ratio is 43.00. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 1858.HK's ROE of +0.04%. Regarding short-term risk, 1612.HK is less volatile compared to 1858.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 1858.HK's competition here
1612.HK vs 1789.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 1789.HK has a market cap of 7.5B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 1789.HK trades at HK$6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 1789.HK's P/E ratio is 25.85. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 1789.HK's ROE of +0.11%. Regarding short-term risk, 1612.HK is less volatile compared to 1789.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 1789.HK's competition here
1612.HK vs 2190.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2190.HK has a market cap of 7B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2190.HK trades at HK$22.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2190.HK's P/E ratio is 67.94. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2190.HK's ROE of +0.03%. Regarding short-term risk, 1612.HK is less volatile compared to 2190.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 2190.HK's competition here
1612.HK vs 6606.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 6606.HK has a market cap of 6.3B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 6606.HK trades at HK$14.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 6606.HK's P/E ratio is 58.92. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 6606.HK's ROE of -0.04%. Regarding short-term risk, 1612.HK is less volatile compared to 6606.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 6606.HK's competition here
1612.HK vs 1763.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 1763.HK has a market cap of 6B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 1763.HK trades at HK$18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 1763.HK's P/E ratio is 12.88. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 1763.HK's ROE of +0.08%. Regarding short-term risk, 1612.HK is less volatile compared to 1763.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 1763.HK's competition here
1612.HK vs 9996.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 9996.HK has a market cap of 5.7B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 9996.HK trades at HK$9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 9996.HK's P/E ratio is -23.24. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 9996.HK's ROE of -0.11%. Regarding short-term risk, 1612.HK is less volatile compared to 9996.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 9996.HK's competition here
1612.HK vs 6669.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 6669.HK has a market cap of 3.7B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 6669.HK trades at HK$12.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 6669.HK's P/E ratio is 62.22. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 6669.HK's ROE of +0.04%. Regarding short-term risk, 1612.HK is less volatile compared to 6669.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 6669.HK's competition here
1612.HK vs 2160.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2160.HK has a market cap of 3.1B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2160.HK trades at HK$1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2160.HK's P/E ratio is -64.00. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2160.HK's ROE of -0.02%. Regarding short-term risk, 1612.HK is less volatile compared to 2160.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 2160.HK's competition here
1612.HK vs 2235.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2235.HK has a market cap of 2.9B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2235.HK trades at HK$6.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2235.HK's P/E ratio is -42.31. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2235.HK's ROE of -0.03%. Regarding short-term risk, 1612.HK is more volatile compared to 2235.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1612.HK.Check 2235.HK's competition here
1612.HK vs 1696.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 1696.HK has a market cap of 2.7B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 1696.HK trades at HK$6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 1696.HK's P/E ratio is 13.98. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 1696.HK's ROE of +0.05%. Regarding short-term risk, 1612.HK is less volatile compared to 1696.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 1696.HK's competition here
1612.HK vs 6609.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 6609.HK has a market cap of 2B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 6609.HK trades at HK$54.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 6609.HK's P/E ratio is -131.59. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 6609.HK's ROE of -0.01%. Regarding short-term risk, 1612.HK is less volatile compared to 6609.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 6609.HK's competition here
1612.HK vs 2500.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2500.HK has a market cap of 1.7B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2500.HK trades at HK$4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2500.HK's P/E ratio is -2.23. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2500.HK's ROE of -0.29%. Regarding short-term risk, 1612.HK is less volatile compared to 2500.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 2500.HK's competition here
1612.HK vs 2216.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2216.HK has a market cap of 1.5B. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2216.HK trades at HK$2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2216.HK's P/E ratio is -11.75. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2216.HK's ROE of -0.09%. Regarding short-term risk, 1612.HK is less volatile compared to 2216.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 2216.HK's competition here
1612.HK vs 2170.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2170.HK has a market cap of 921.9M. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2170.HK trades at HK$3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2170.HK's P/E ratio is -3.27. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2170.HK's ROE of -0.20%. Regarding short-term risk, 1612.HK is less volatile compared to 2170.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 2170.HK's competition here
1612.HK vs 6118.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 6118.HK has a market cap of 661.2M. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 6118.HK trades at HK$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 6118.HK's P/E ratio is 43.00. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 6118.HK's ROE of +0.02%. Regarding short-term risk, 1612.HK is less volatile compared to 6118.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 6118.HK's competition here
1612.HK vs 2297.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2297.HK has a market cap of 518.5M. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2297.HK trades at HK$0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2297.HK's P/E ratio is -3.36. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2297.HK's ROE of -0.26%. Regarding short-term risk, 1612.HK is less volatile compared to 2297.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 2297.HK's competition here
1612.HK vs 2393.HK Comparison August 2025
1612.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1612.HK stands at 559.7M. In comparison, 2393.HK has a market cap of 422M. Regarding current trading prices, 1612.HK is priced at HK$0.86, while 2393.HK trades at HK$0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1612.HK currently has a P/E ratio of 7.91, whereas 2393.HK's P/E ratio is 0.42. In terms of profitability, 1612.HK's ROE is +0.12%, compared to 2393.HK's ROE of +1.71%. Regarding short-term risk, 1612.HK is less volatile compared to 2393.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1612.HK.Check 2393.HK's competition here